Pulmonary Arterial Hypertension Market, by Drug Type (Endothelin Receptor Antagonists (ERAs), Phosphodiesterase-5 (PDE-5) Inhibitors, Soluble Guanylate Cyclase (sGC) Stimulators, Prostacyclin Analogue, Calcium Channel Blockers, and Others), by Route of Ad

Pulmonary Arterial Hypertension Market, by Drug Type (Endothelin Receptor Antagonists (ERAs), Phosphodiesterase-5 (PDE-5) Inhibitors, Soluble Guanylate Cyclase (sGC) Stimulators, Prostacyclin Analogue, Calcium Channel Blockers, and Others), by Route of Administration (Oral, Inhaled, Intravenous, and Subcutaneous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Pulmonary arterial hypertension is a rare diseases that is caused due to various factors such as congestive heart failure, liver diseases, autoimmune diseases, which includes Lupus, scleroderma, rheumatoid arthritis, and others. This disease is considered rare but life-threatening condition that gets worse over time. The narrowed and blocked arteries with the high pressure of blood is called as pulmonary arterial hypertension (PAH) and pulmonary hypertension (PH). The tiny arteries in the lungs become narrow and blocked, which makes difficult to pump blood through these arteries and later leads to weaken the heart muscle. Rising cases of causes of pulmonary arterial hypertension (PAH) is expected to fuel growth of the market in the forecast period. For instance, according to the American College of Cardiology Foundation published an article Heart Disease and Stroke Statistics-2019, a report from the American Heart Association, around 795,000 U.S. population have a new or recurrent stroke annually, in which 90.0% of stroke risk is due to modifiable risk factors and 74.0% is due to behavioral risk factors.
Furthermore, approvals of drugs through the regulatory bodies for the treatment of pulmonary arterial hypertension (PAH) are expected to fuel growth of the market. For instance, in September 2017, Actelion Pharmaceuticals, Ltd. received a New Drug Application (NDA) approval from the U.S. Food and Drug Administration for Tracleer (bosentan), a 32 mg dispersible tablets. This drug got approval for the treatment of Pulmonary Arterial Hypertension in adult and pediatric patients.
Market Dynamics
The pulmonary arterial hypertension (PAH) market is expected to witness significant growth over the forecast period, owing to increasing number of heart failures which later leads to pulmonary arterial hypertension (PAH) cases. For instance, in 2019, Heart Failure Society of America reports that around 550,000 new cases of heart failure are diagnosed each year in the U.S. and nearly 1.4 million persons with congestive heart failure (CHF) are under 60 years of age.
Product approvals by regulatory authorities are expected to drive growth of pulmonary arterial hypertension (PAH) market over the forecast period. For instance, in 2013, the U.S. Food and Drug Administration approved Actelion Ltds’ Opsumit (Macitentan) for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression. The drug is novel dual endothelin receptor antagonist (ERA), a 10 mg oral tablet available to address efficacy and safety.
Moreover, in November 2021, Arena Pharmaceuticals and United Therapeutics entered into an exclusive license agreement related to Ralinepag (Potent IP Receptor Agonist), which was evaluated for the treatment of pulmonary arterial hypertension. Under the agreement, United Therapeutics got an exclusive and irrevocable license to develop, manufacture and commercialize ralinepag in any formulation for pulmonary arterial hypertension (PAH).
Key features of the study:
This report provides in-depth analysis of the pulmonary arterial hypertension (PAH) market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global pulmonary arterial hypertension (PAH) market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as part of this study include United Therapeutics Corporation, GlaxoSmithKline plc, Novartis AG, AstraZeneca, Bayer AG, Merck KGaA, Pfizer Inc., Gilead Sciences, Inc., Actelion Pharmaceuticals Ltd, Arena Pharmaceuticals, and Daiichi Sankyo Company, Limited.
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future product launches, technology upgradation, market expansion, and marketing tactics
The global pulmonary arterial hypertension (PAH) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Pulmonary Arterial Hypertension (PAH) market
Detailed Segmentation:
Global Pulmonary Arterial Hypertension (PAH) market, By Drug Type:
Endothelin Receptor Antagonists (ERAs)
Phosphodiesterase-5 (PDE-5) Inhibitors
Soluble Guanylate Cyclase (sGC) Stimulators
Prostacyclin Analogue
Calcium Channel Blockers
Others
Global Pulmonary Arterial Hypertension (PAH) market, By Route of Administration:
Oral
Inhaled
Intravenous
Subcutaneous
Global Pulmonary Arterial Hypertension (PAH) market, By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Pulmonary Arterial Hypertension (PAH) market, By Region:
North America
By Drug Type:
Endothelin Receptor Antagonists (ERAs)
Phosphodiesterase-5 (PDE-5) Inhibitors
Soluble Guanylate Cyclase (sGC) Stimulators
Prostacyclin Analogue
Calcium Channel Blockers
Others
By Route of Administration:
Oral
Inhaled
Intravenous
Subcutaneous
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Latin America
By Drug Type:
Endothelin Receptor Antagonists (ERAs)
Phosphodiesterase-5 (PDE-5) Inhibitors
Soluble Guanylate Cyclase (sGC) Stimulators
Prostacyclin Analogue
Calcium Channel Blockers
Others
By Route of Administration:
Oral
Inhaled
Intravenous
Subcutaneous
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Type:
Endothelin Receptor Antagonists (ERAs)
Phosphodiesterase-5 (PDE-5) Inhibitors
Soluble Guanylate Cyclase (sGC) Stimulators
Prostacyclin Analogue
Calcium Channel Blockers
Others
By Route of Administration:
Oral
Inhaled
Intravenous
Subcutaneous
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Type:
Endothelin Receptor Antagonists (ERAs)
Phosphodiesterase-5 (PDE-5) Inhibitors
Soluble Guanylate Cyclase (sGC) Stimulators
Prostacyclin Analogue
Calcium Channel Blockers
Others
By Route of Administration:
Oral
Inhaled
Intravenous
Subcutaneous
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Pakistan
Rest of Asia Pacific
Middle East
By Drug Type:
Endothelin Receptor Antagonists (ERAs)
Phosphodiesterase-5 (PDE-5) Inhibitors
Soluble Guanylate Cyclase (sGC) Stimulators
Prostacyclin Analogue
Calcium Channel Blockers
Others
By Route of Administration:
Oral
Inhaled
Intravenous
Subcutaneous
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Drug Type:
Endothelin Receptor Antagonists (ERAs)
Phosphodiesterase-5 (PDE-5) Inhibitors
Soluble Guanylate Cyclase (sGC) Stimulators
Prostacyclin Analogue
Calcium Channel Blockers
Others
By Route of Administration:
Oral
Inhaled
Intravenous
Subcutaneous
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
North Africa
Central Africa
South Africa
Company Profiles
United Therapeutics Corporation*
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Market Strategies
GlaxoSmithKline plc.
Novartis AG
AstraZeneca
Bayer AG
Merck KGaA
Pfizer Inc.
Gilead Sciences, Inc.
Actelion Pharmaceuticals Ltd
Arena Pharmaceuticals
Daiichi Sankyo Company, Limited
“*” marked represents similar segmentation in other categories in the respective section.